Vanda Pharmaceuticals

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vanda Pharmaceuticals reports mixed Q4 results amid legal challenges and opportunities

Vanda Pharmaceuticals faces financial challenges with declining revenues and HETLIOZ sales, offset by increased cash reserves and positive clinical trial outcomes.
Legal battles and uncertainties add complexity to the company's financial outlook, requiring strategic planning and risk management.
Despite hurdles, opportunities for growth exist through new drug applications, market expansion, and potential partnerships to drive future success.

Vanda Pharmaceuticals reports resilient Q1 performance amidst generic challenges

Vanda Pharmaceuticals delivered a strong performance in Q1 2023, navigating challenges from generic competition while focusing on growth opportunities.
The company's financial results and strategic initiatives position it well for future expansion and innovation in the pharmaceutical industry.
Despite uncertainties surrounding litigation and generic competition, Vanda remains resilient and committed to driving long-term value for stakeholders.

Vanda Pharmaceuticals navigates revenue decline, eyes regulatory approvals for growth

Vanda Pharmaceuticals faced revenue challenges due to generic competition impacting HETLIOZ sales, leading to a revenue decline.
Despite legal uncertainties and revenue setbacks, the company showcased strength in pipeline progress and operational cost management.
Management's confidence in regulatory outcomes and strategic flexibility positions Vanda for potential growth opportunities.

Vanda Pharmaceuticals reports revenue decline but maintains positive net income

Vanda Pharmaceuticals faces revenue challenges with declining total revenues and net product sales in 2023.
Despite this, the company maintains positive net income and focuses on upcoming FDA decisions for growth.
Strong leadership, operational efficiency, and a diversified product portfolio are key strengths for Vanda.
Exploring growth opportunities through FDA decisions, market expansion, and strategic initiatives is crucial for future success.

Vanda Pharmaceuticals reports revenue decline, pursues new treatments amid challenges

Vanda Pharmaceuticals faced revenue declines and net losses in Q4 2023, driven by challenges in product sales and market conditions.
Despite these setbacks, the company is strategically expanding its product portfolio and pursuing new treatments to drive future growth.
Navigating legal battles, generic competition, and market uncertainties will be key focus areas for Vanda in the coming year.

Vanda Pharmaceuticals navigates revenue challenges, eyes growth through strategic initiatives

Vanda Pharmaceuticals faced revenue challenges due to generic competition but remains focused on driving growth through commercial strategies.
The company's psychiatry portfolio expansion and ongoing clinical programs position it well for future market opportunities.
Addressing shareholder activism and evaluating takeover proposals while maintaining operational focus are key challenges ahead.
Engaging with the FDA for product approvals and planning strategic marketing initiatives offer avenues for revenue growth.

Vanda Pharmaceuticals reports revenue growth and strategic expansion plans

Vanda Pharmaceuticals is navigating a mixed financial performance with revenue growth but a net loss in Q2 2024. The company's focus on expanding its commercial organization and advancing clinical development indicates a strategic approach to drive future growth amidst challenges from generic competition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

No Shareholder Action Required at This Time WASHINGTON , June 6, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. ("Cycle Group") to acquire the Company for $8.00 per share in cash.

Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) is up nearly 20% on Thursday following a report that Cycle Pharmaceuticals Ltd is interested in taking over the Washington-based company.  Vanda Pharmaceuticals stock valued at $8.0 Anonymous sources told Bloomberg this morning that Cycle Pharma has made an unsolicited buyout offer that values $VNDA at about $460 million.

Vanda Pharmaceuticals stock: why is it up 20% on Thursday?

BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (“Cycle” or the “Company”), a rapidly growing pharmaceutical company focused on treatments for the underserved rare disease patient community, today confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) on May 24, 2024 to acquire 100% of Vanda's issued and outstanding shares for a cash consideration of $8.00 per Vanda share, representing a total cash consideratio.

Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share

WASHINGTON , May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2024 Global Healthcare Conference in New York City on Thursday, June 6, 2024. A corporate presentation is scheduled for 2:00 p.m.

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference

WASHINGTON , May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that ownership of the U.S. New Drug Application and Investigational New Drug Applications for PONVORY® (ponesimod) has been transferred to Vanda from a Johnson & Johnson Company, which now fully allows Vanda to commercialize PONVORY® in the U.S. "This milestone completes the transfer of the FDA marketing authorization to Vanda and allows Vanda to commence full commercialization efforts and begin clinical development programs as we seek to maximize the potential of Ponvory in the treatment of a host of inflammatory disorders," said Mihael H. Polymeropoulos, M.D.

Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®

WASHINGTON , May 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024. The following will be presented: June 4, 2024 Presentation Title: "Drug Screening and CRISPR/Cas9 Screening of HCN Channels"Poster Presentation Session: P-17Poster Number: 10Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics Presentation Title: "Melanopsin Crispants in Zebrafish Display Difference in Sleep Latency"Poster Presentation Session: P-17Poster Number: 11Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics Presentation Title: "Genetic Variants Associated with Dim Light Melatonin Onset in a Delayed Sleep-Wake Phase Disorder Cohort"Poster Presentation Session: P-22Poster Number: 146Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics Presentation Title: "Genetic variants associated with TST and LPS in insomnia patients: whole genome sequencing study"Poster Presentation Session: Late-Breaking Abstracts (LBA); P-31Poster Number: 451Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics For more information on SLEEP 2024, please refer to https://www.sleepmeeting.org/ About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.

Vanda Pharmaceuticals Announces Presentations at SLEEP 2024

WASHINGTON , May 24, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board") carefully reviewed the revised unsolicited proposal from Future Pak, LLC ("FP") to acquire the Company for $7.25 to $7.75 per share in cash plus certain Contingent Value Rights ("CVRs") and, after having consulted with the Company's independent financial and legal advisors, unanimously concluded that the proposal substantially undervalues the Company, creates significant risk and uncertainty and is not in the best interests of the Company and its shareholders. Accordingly, the Board has rejected the proposal.

Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders

Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.

Vanda (VNDA) Rises on Positive Data From Motion Sickness Study

•         New Drug Application expected to be submitted in Q4 2024 WASHINGTON , May 15, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. This Phase III study was conducted in real-world conditions on boats in the coastal waters of the United States (U.S.).

Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness

Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Mihael Polymeropoulos - President, Chairman and CEO Kevin Moran - CFO Tim Williams - Senior Vice President and General Counsel Conference Call Participants Operator Thank you for standing by. My name is Hermine, and I will be your conference operator today.

Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript

Revenues for Q1 2024 were $47.5 million, an increase of 5% compared to Q4 2023 Cash increase of $5.9 million in Q1 2024 to $394.1 million Fanapt® approved for the acute treatment of bipolar I disorder; commercial launch expected in Q3 2024 Milsaperidone NDA for schizophrenia and bipolar disorder expected to be submitted in early-2025 PONVORY® commercial launch expected in Q3 2024 Tradipitant NDA review for gastroparesis ongoing, PDUFA date of September 18, 2024 Tradipitant second Phase III motion sickness study results expected in Q2 2024; NDA expected to be submitted in Q4 2024 WASHINGTON , May 8, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2024. "We are very proud of our accomplishments in the first quarter of 2024, which were achieved with a small but efficient organization that is enthusiastic to continue developing and commercializing treatments for people who need them," said Mihael H.

Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results

WIXOM, Mich.--(BUSINESS WIRE)--Future Pak LLC (“Future Pak”) confirms it increased its offer for all outstanding shares of common stock of Vanda Pharmaceuticals (“Vanda” or “the Company”) (NYSE: VNDA) to include Contingent Value Rights (“CVRs”) in addition to the cash consideration of $7.25 to $7.75 per share (the “Revised Proposal”), representing a potential increase of approximately $4.37 per share from the prior proposal announced on April 17, 2024. This increased offer, assuming full trigge.

Future Pak Increases Bid for Vanda Pharmaceuticals to Include CVRs in Addition to $7.25 to $7.75 Per Share in Cash

Conference Call and Webcast to Follow WASHINGTON , April 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2024 on Wednesday, May 8, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 8, 2024, during which management will discuss the first quarter 2024 financial results and other corporate activities.

Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024

Investment firm Shareholder Capital sent a letter to drugmaker Vanda Pharmaceuticals' board on Thursday asking it to reconsider Future Pak's takeover offer.

Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer

WASHINGTON , April 22, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp.  "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation," said Dr. Mihael H.

Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation

The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva and Apotex.

U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents

Hedge fund manager Butler Hall Capital said on Friday it is urging Vanda Pharmaceuticals to form an independent special committee to engage with Future Pak over its takeover offer and run a full sales process.

Butler Hall Capital urges Vanda to engage in sales discussions

Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.

Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up

Zacks.com users have recently been watching Vanda (VNDA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know

Vanda confirmed it received several unsolicited acquisition offers from Future Pak. The company's board rejected these proposals, stating that Vanda is worth more than the offered price.

Why Vanda Pharmaceuticals Stock Is Skyrocketing Today

WASHINGTON , April 17, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights plan (the "Rights Plan") to protect stockholder interests and maximize value for all stockholders. The Rights Plan is effective immediately.

Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

Vanda Pharmaceuticals Inc on Wednesday said it is rejecting a takeover proposal from Future Pak, a privately-held contract manufacturer and packager of pharmaceuticals, as it significantly undervalues the company.

Vanda Pharmaceuticals rejects takeover proposal from Future Pak

Board Determined Unsolicited Takeover Proposals Significantly Undervalue the Company No Shareholder Action Required at This Time WASHINGTON , April 17, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that, since March 2024, it received several unsolicited proposals from Future Pak, LLC ("Future Pak"), to acquire all of the outstanding shares of Vanda (the "Conditional Proposals"). The most recent proposal from April 1 offered $7.25 - $7.75 per share, subject to certain terms and conditions.

Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak

Vanda Pharmaceuticals (NASDAQ: VNDA ) stock is rising higher on Wednesday after the biopharmaceutical company received a firm acquisition proposal from Future Pak LLC. Vanda Pharmaceuticals has received three proposals from Future Pak LLC to acquire the company since February.

Why Is Vanda Pharmaceuticals (VNDA) Stock Up 34% Today?

WIXOM, Mich.--(BUSINESS WIRE)--Future Pak LLC (“Future Pak”) today announced that it has submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA), and confirms that its most recent proposal to acquire Vanda for cash consideration of $7.25 to $7.75 per share remains open for Vanda and its Board of Directors to consider. The current proposal implies a premium of 79.0% to 91.4% to Vanda's closing price.

News for Vanda Pharmaceuticals Stock (VNDA)